2nd CRISPR-Based Therapy Analytical Development Summit
Evvnt Promotion / evvnt
17.09.2024 - 19.09.2024 Hilton Boston Logan Airport, One Hotel Drive, 02128 Boston, Massachusetts, USA
Time: 9:00 AM - 5:00 PM
Kongressthemen
As CRISPR-based therapies become ever complex, drug developers urgently need to innovate the analytical tools available to effectively characterize their safety and efficacy profiles and agree upon gold standards moving forward. We are also witnessing increased regulatory scrutiny, with the FDA closely studying off-target analysis conducted ahead of the approval of Casgevy, prior to finalizing guidance on genome editing therapies in January.
As CRISPR-based therapies become ever complex, drug developers urgently need to innovate the analytical tools available to effectively characterize their safety and efficacy profiles and agree upon gold standards moving forward. We are also witnessing increased regulatory scrutiny, with the FDA closely studying off-target analysis conducted ahead of the approval of Casgevy, prior to finalizing guidance on genome editing therapies in January.
Kongressorganizer (PCO)
Hanson Wade
Hanson Wade
Anmerkungen
URL:
Brochure: https://go.evvnt.com/2433843-3?pid=4832
Speakers: Andrew Kernytsky, Principal Consultant, Next Gen Editing, Bryant Chia, Scientist, Analytical Chemistry and Structural Biology, Editas Medicine, and more
URL:
Brochure: https://go.evvnt.com/2433843-3?pid=4832
Speakers: Andrew Kernytsky, Principal Consultant, Next Gen Editing, Bryant Chia, Scientist, Analytical Chemistry and Structural Biology, Editas Medicine, and more
Anfragen und Anmeldung:
https://go.evvnt.com/2433843-2?pid=4832
Frau Jasmine Fletcher
Allgemeinmedizin
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
83 Great Titchfield Street
W1W 6RH London
Großbritannien
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."
